1103326-0282

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

: Cederberg et al.

Serial No.

: 08/945,425

Filed

: October 21, 1997

For

: ADMINISTRATION OF PHARMACEUTICALS

Examiner

: Desai, R.

Group Art Unit

: 1612

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. 1.8

I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office on March 8, 2002 at the facsimile number 703-308-7922.

John M. Genova

32 224

Attorney Name

PTO Reg. No.

Signature Signature

Date of Signature

Box AF

Assistant Commissioner for Patents Washington, D.C. 20231

ATTENTION:

Examiner R. Desai

FACSIMILE NO:

703-308-7922

DATE:

March 8, 2002

PAGES:

22 pages

 INFORMATION DISCLOSURE STATEMENT FILED CONCURRENTLY WITH REQUEST FOR CONTINUED EXAMINATION

Sir:

Applicants submit this communication in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. A Request for Continued Examination ("RCE") is being submitted concurrently with this Information Disclosure Statement as a separate paper. Applicants request consideration of the

patentability of the claimed invention in view of the documents listed on Form PTO-1449 attached herewith.

REMARKS

The referenced application is a CPA of U.S. Patent Application 08/945,425, which is a §371 application of PCT/SE97/01098, filed June 18, 1997. The PCT application claims priority to Swedish Patent Application No. 9602442-7, filed June 20, 1996. A final Office Action issued September 13, 2001.

In an Information Disclosure Statement ("IDS"), mailed April 7, 1999, Applicants identified the document WO 97/02020, published January 23, 1997 (the "WO publication"). In a supplemental IDS, mailed November 1, 1999, Applicants identified US 5,945,124, issued August 31, 1999 (the "124 patent). The WO publication corresponds to international application No. PCT/EP96/02892 which claims priority to the application underlying the '124 patent.

The following three documents cited in the attached Form PTO-1449 are related to the '124 patent and the WO publication:

- US 6,068,856, issued May 30, 2000 (the "'856 patent") is a divisional of the '124 patent;
- US 6,274,173 is a continuation of the '856 patent; and
- US 6,132,768 is related to the '124 patent stated in col. 1, lines 8-10, of the '124 patent.

In view of the foregoing, it is submitted that the documents cited on the attached Form PTO-1449 as part of this Information Disclosure Statement are substantively cumulative vis-à-vis the previously cited '124 patent and the WO publication.

TIME OF TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

The Information Disclosure Statement transmitted herewith is being filed concurrently with a Request for Continued Examination and therefore no separate fee is due. However, authorization is hereby given to charge Account No. 23-1703 for any fee which may be due in connection with this communication.

Dated: March 8, 2002

Respectfully submitted,

An M Person

John M. Genova Reg. No. 32,224

Attorney for Applicants Customer No. 007470

Attorney Direct Dial: (212) 819-8832